One of the challenges facing researchers working with viruses and gene therapy vectors is the need to rapidly assay for infectious virus. Current methods used to titer many viruses are cumbersome and are not amenable to handling large numbers of samples. Here we describe the development of an assay that can rapidly quantify infectious viruses and gene therapy vectors. The assay relies on biological amplification of viral sequences and hybridization of labeled probes to immobilized nucleic acid from infected cells. The amplification of the viral genome makes this a highly sensitive method. The assay is configured in a high-throughput format that has been used to detect recombinant adeno-associated virus (AAV), wild-type AAV and infectious adenovirus. The assay is quantitative, and can be used to titer virus preparations with or without a known standard.
In order to determine the titer of a viral preparation, researchers routinely rely on assays that indicate successful infection and replication events. In the case of lytic viruses, successful infection and replication results in cell death, causing plaques to form in a lawn of cells. Plaque detection is quantitative, but labor-intensive and cannot be applied to non-cytopathic viruses. A viral preparation can be titered by serial dilution of a sample to determine the tissue-culture infected dose at 50% (TCID 50 ) (1) . Viral infection is scored with a marker of virus replication, such as cell death, hybridization to detect replicated viral nucleic acid, or immunofluoresecence with a virus-specific antibody to detect viral proteins in a cell (2, 3) . Titer determination and comparison of recombinant viruses used in gene therapy is difficult. Transduction assays can measure gene transfer and expression, but are often confounded by cell and tissue specificity, variable transduction efficiency, and variable expression of reporter genes, different promoters, etc. Comparison of different vector titers is problematic. Direct physical measurements of viral particles (4) or genomes can be confounded by the presence of defective-interfering particles (DIs) (3). Variation in particle-to-infectivity ratios can span logs for a given virus or vector.
We have developed a rapid and quantitative method to measure viral titer after amplification of viral genetic material on a host cell line. This report focuses on quantification of a lytic virus, adenovirus type 5, a non-cytopathic virus, adeno-associated virus (AAV), and a recombinant AAV vector carrying the cystic fibrosis transmembrane conductance regulator (CFTR). The assay relies on infection of cells with a virus preparation, replication of the virus genome in the host cell, chemical lysis of the cell, and nucleic acid hybridization. In a 96-well microtiter array, the assay can be performed with automated pipettors with minimal labor. Data analysis is rapid. Scanned blots can be analyzed quickly using spreadsheets, and statistical assay control can be applied to each assay. Large numbers of samples can be processed in a short period of time.
The assay was initially used to quantify the recombinant AAV-CFTR vector. The vector, tgAAVCF, was produced as published previously (5, 6) . Briefly, 293-1 cells were incubated with Ad5 (MOI = 5) for 1 h. The cells were then transfected with a packaging plasmid, pRS5 (6), containing AAV rep and cap, and the tgAAVCF vector construct. The vector was purified on two successive cesium chloride gradients, and the bands were pooled, dialyzed against Ringer's balanced salt solution (RBSS) + 5% glycerol. Any residual Ad5 was heat inactivated at 56_C. Titer of the standard AAV stocks was determined by the infectious center assay (2) .
For the microtiter assay, a host cell line was required that could amplify the recombinant AAV. The HeLa C37 line used to titer this vector contains a cassette with the wild-type AAV rep/cap genes from nt 311 to 4493 of the AAV genome operably linked to the mouse metallothionein I (mMT1) gene promoter from -590 to +64 relative to the start of transcription (7-10). C37 was selected for the ability to amplify AAV genomes in the presence of adenovirus (data not shown). For the microtiter assay, cells were plated in a 96-well tissue culture dish and allowed to settle for 4-16 h. The cells were then infected with aliquots of vector. Standard vector preparations of known titer were placed on the plate in serial dilutions, and an internal control of known titer was also used. Ad5 was added to each well at MOI = 10. The infection was allowed to proceed for 48-72 h, at which point the cells were lysed by the addition of 1/10 vol 4 M NaOH, 50 mM EDTA, 10 µg/ml salmon testes DNA. The plate was incubated at 65_C for 30 min, and cells were inspected for lysis. The contents of the wells were then transferred to a rinsed 96-well plate with a positively-charged nylon membrane bottom (Pall Biomedical, Biodyne B). The lysate was filtered through the membrane on a vacuum manifold, and the wells were washed with 0.4 M NaOH. Blots were probed with the 1488 bp EcoRI CFTR fragment by standard techniques (11) . Quantitation of signal on the blots was *To whom correspondence should be addressed. Tel: +1 206 521 7828; Fax: +1 206 223 0288; Email: atkinson@targen.com done on a Phosphorimager, using an 8 × 12 grid. Pixel counts were directly plotted on Microsoft Excel versus input units of virus. Figure 1A shows the blot of the microplate assay with AAV-CF samples versus a standard curve of AAV-CF with known titer. Internal controls of 300 and 1000 infectious units (IU)/well are included in duplicate. In Figure 1B , the signal is plotted for both AAV samples over a wide dilution range. The assay saturates at the lower dilutions, but approximates linear over a certain range for both samples. Figure 1C shows the response over the linear portion of the standard curve, from 75 to 600 IU/well (r 2 = 0.987). Using a linear regression, the assay can be used to reliably estimate the amount of infectious material present in a recombinant AAV preparation. The 300 IU control gives a value of 260 IU, while the 1000 IU control is not in the linear range of the assay. When adenovirus was omitted, the signal was indistinguishable from background (data not shown), indicating that the single-copy endogenous CFTR sequences are below the limit of detection and no input rAAV-CF signal was observed. The format of this blot was set up with samples in triplicate for statistical purposes, but by rearranging the position of samples in a plate with fewer dilutions, many more samples can be assayed at once with the required standards and internal control.
Having used the microtiter array format for titering recombinant AAV, we then used the same format to titer samples containing adenovirus. Typically, TCID 50 or plaque assays are used to quantify adenovirus, and both techniques are used to titer our adenoviral stocks. We found that the microtiter assay was equally reliable, but required only 48 h to complete. HeLa (ATCC) cells were used in the 96-well plates exactly as the C37 cells above, and assays were harvested at 48 h. Ad5 blots were probed with a 344 bp PCR-amplified sequence specific for the adenovirus E1A gene (primers: 5′-TATTACCGAAGAAATGGCCG-3′ and 5′-GGACG-GTAAGATCGATCACC-3′). Figure 2 illustrates the utility of the assay for adenovirus type 5. The blot contains triplicate serial 10-fold dilutions of untitered Ad5, versus a duplicate standard of adenovirus of known titer. Internal controls of a second adenovirus preparation of known titer at 50 and 300 IU/well were included in duplicate. The assay shows a similar response over the 10-fold dilutions, saturating at high titers (Fig. 2B) . When the linear range of the curve representing an Ad5 preparation of known titer is plotted (Fig. 2C) , it shows a response that closely approximates linear (r 2 = 0.991) up to 500 IU/well. Using the least squares regression for this curve, the internal controls return values of 65 and 332 IU/well, respectively.
As the microtiter assay showed a linear response to recombinant AAV and Ad5, it was tested to determine if the response to wild-type AAV would also be linear. Wild-type AAV replicates efficiently in the presence of adenovirus (12) . In the microtiter format, the linear range was highly compressed using wt AAV in the presence of Ad5, even after varying the infection time from 40 to 72 h. The presence of a single infectious unit of wtAAV caused a signal above background in a well, but the response range was very narrow, saturating at >10 IU/well (data not shown). This is likely due to the high burst size of wtAAV. In this case, the assay was then used in a limiting dilution TCID 50 -style format to determine the titer of wtAAV. As in a TCID 50 , eight serial limiting dilutions of a wtAAV preparation of known titer were prepared and assayed in the microtiter assay. The blot was probed for the AAV rep sequence, and a positive signal in a well indicated the presence of at least 1 IU of infectious wt AAV (Fig. 3) . The titer was calculated by a standard TCID 50 50% end-point analysis (1) using Poisson statistics to determine viral titer. The results of this assay corresponded exactly with the value obtained with detection by Rep immunofluorescence (3). The titer for the sample in Figure 3 , by both techniques, was 3 × 10 9 IU/ml. This indicates that the microtiter format is suitable as a direct titering assay for wtAAV, without the use of a standard of known titer. The assay was much more rapid than immunostaining and scanning for Rep positive nuclei.
The natural ability of viruses to replicate to high copy numbers provides an opportunity to use a biological amplification mechanism to detect small quantities of material. The methods outlined in this study present a format for utilizing this amplification in a wide variety of experiments involving both replication-competent viruses and gene therapy vectors. The assay would be of utility in screening for agents that inhibit viral replication. The use of adenovirus, wild-type adeno-associated virus, and recombinant AAV indicates that this is of broad application. In theory, retroviral and non-viral gene delivery systems are also amenable to the assay format described here. The necessary component is a cell line that enables the virus to amplify its genetic material to the point of detection by simple hybridization techniques. The utility of such cell lines for AAV assays has recently been demonstrated (13) . By either limiting dilution or comparison to a known standard, a titer can be determined which corresponds to the titers determined by more classical techniques. This also provides a method for titering replication incompetent viruses or vectors. To determine the actual transducing power of a recombinant vector preparation, assays that do not rely on biological amplification in the permissive cell line are still necessary, as engineered cell lines will undoubtedly behave differently than primary cells in vitro or in vivo. When screening for permissive cell lines and production lines, the microtiter format can serve as both a replication and infectivity assay. We have used this method to select viral producer lines, screening a large number of possible packaging lines at the same time. It is also worth noting that to get a truly accurate quantitation of an infectivity assay, it is imperative that serial dilutions are used; at or beyond saturation the response of the microtiter assay is not linear. At high titer, two preparations may differ by 1000-fold, but the response of the assay would not reflect this fact. The use of assay standards and controls is recommended, as with any biological measurement, to gain statistical control and increased confidence in the quantitative data.
